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Abstract
The penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA), which exists as an 
oily liquid, was incorporated into a solid dispersion for oral administration by the solvent 
evaporation method using blends of polyvinylpyrrolidone (PVP), Eudragit® RL PO and α-
tocopherol. D-optimal mixture design was used to optimize the formulation. Formulations that had 
a high concentration of both Eudragit® RL PO and α-tocopherol exhibited low water absorption 
and enhanced stability of the DTPA prodrug. Physicochemical properties of the optimal 
formulation were evaluated using Fourier transform infrared (FTIR) spectroscopy and differential 
scanning calorimetry (DSC). In vitro release of the prodrug was evaluated using the USP Type II 
apparatus dissolution method. DSC studies indicated that the matrix had an amorphous structure, 
while FTIR spectrometry showed that DTPA penta-ethyl ester and excipients did not react with 
each other during formation of the solid dispersion.. Dissolution testing showed that the optimized 
solid dispersion exhibited a prolonged release profile, which could potentially result in a sustained 
delivery of DTPA penta-ethyl to enhance bioavailability. In conclusion, DTPA penta-ethyl ester 
was successfully incorporated into a solid matrix with high drug loading and improved stability 
compared to prodrug alone.
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Introduction
Diethylenetriaminepentaacetic acid (DTPA) is a chelating agent that can be used for 
decorporation of plutonium (Pu), americium (Am) and curium (Cm) after accidental or 
deliberate internal contamination in humans.[1] After such a contamination event, DTPA is 
usually administered to the patient by intravenous (i.v.) injection.[2, 3] However, injection of 
DTPA requires a well-trained medical professional, which poses a logistical challenge for 
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treating patients in a mass casualty scenario. To facilitate drug distribution and allow for 
self-dosing, a number of strategies, including DTPA-entrapped dry powder for pulmonary 
delivery, have been pursued.[4, 5] An oral dosage form that could be distributed readily and 
to large numbers of people would be ideal in the case of a wide-spread contamination 
emergency. DTPA, however, is hydrophilic, highly ionizable and, thus, is poorly absorbed 
from the gastrointestinal tract with a bioavailability of <1% in humans.[6] To overcome this 
drawback, we prepared a lipophilic prodrug of DTPA by esterifying its five carboxylic acid 
functional groups and measured the octanol-water partition coefficient of DTPA penta-ethyl 
ester at various pH values which indicated that this prodrug would be a good candidate for 
intestinal delivery.[7] We demonstrated that DTPA penta-ethyl ester was absorbed after oral 
administration to rats and enzymatically converted to partially-de-esterified metabolites 
capable of chelating transuranic elements.[8] We further demonstrated the radionuclide 
decorporation efficacy of DTPA penta-ethyl ester when administered orally in soybean oil 
or acetate buffer to rats that had been contaminated with 241Am, an alpha particle-emitting 
transuranic radionuclide.[9] Because DTPA penta-ethyl ester exists as an oily liquid, 
formulating it in a solid dosage form would be very desirable in terms of ease of packaging, 
handling and administering. The solid dispersion approach has been used previously[10, 11]; 
it allows for a more uniform product than does mechanical mixing of liquids with solids. In 
addition, solid dispersions of poorly water soluble active pharmaceutical ingredients can 
increase solubility, dissolution rate and bioavailability.[12]
In this study, the DTPA penta-ethyl ester-containing matrix was prepared by solid dispersion 
using water-soluble polyvinylpyrrolidone (PVP), water insoluble Eudragit® RL PO 
polymers and α-tocopherol. PVP is commonly used as a disintegrant in pharmaceutical 
tablets[13, 14] and has been used for the preparation of binary solid dispersion systems for 
various drugs.[15, 16] Eudragit® RL PO is composed of poly(ethylacrylate-
methylmethacrylate-trimethylammonioethyl methacrylate chloride) copolymers, and is inert 
to digestive tract contents, pH independent, and capable of swelling due to the presence of 
quaternary ammonium groups, and, thus, is utilized for formulating extended-release dosage 
forms.[17, 18] It was expected that utilizing Eudragit® RL PO would enhance the absorption 
of DTPA penta-ethyl ester after oral administration. The antioxidant α-tocopherol was used 
to maintain the stability of DTPA penta-ethyl ester.[19] The DTPA penta-ethyl ester has five 
ester groups, which can be hydrolyzed and oxidized in high relative humidity and 
temperature environments;[20] thus, our design maximized drug stability and drug loading, 
and minimized water absorption. In this investigation, the D-optimal mixture design[21, 22] 
was used to select the optimum formulation. Interaction of DTPA penta-ethyl ester in the 
solid dispersion were investigated by Fourier transform infrared (FTIR) spectroscopy and 
differential scanning calorimetry (DSC). In vitro release of DTPA penta-ethyl ester from the 
optimized formulation in 0.1 N HCl (pH 1.2) and phosphate buffer (pH 6.8) were 
investigated.
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PVP (MW: 360,000 g mol−1) was supplied by Fluka (Switzerland), Eudragit® RL PO was 
obtained from Rohm Pharma GmbH (Darmstadt, Germany), α-tocopherol was from Sigma-
Aldrich (St Louis, MO), absolute ethanol, isopropanol and acetonitrile were purchased from 
Acros Organics (New Jersey, USA), and DTPA penta-ethyl ester was prepared as described 
previously.[7]
Preparation of solid dispersions of DTPA penta-ethyl ester and optimization
Preparation of solid dispersions of DTPA penta-ethyl ester—Solid dispersions of 
DTPA penta-ethyl ester entrapped in the excipients (PVP, Eudragit® RL PO and α-
tocopherol) were prepared by the solvent evaporation method.[12] The amount of DTPA 
penta-ethyl ester was fixed at 375 mg (75%) and excipients at 125 mg (25%). DTPA penta-
ethyl ester with different ratios (Table 1) of the three excipients were dissolved in 0.3 mL 
absolute ethanol and stirred for 1 h. A 0.15 mL aliquot of the DTPA penta-ethyl ester 
excipient mixture was subsequently transferred to a round bottom 96-well plate. The 
resulting solid dispersion was dried at 40°C for 24 h.
D-optimal mixture design—In order to optimize the formulation, the Design of Expert 
software program (version 8, Stat-Ease Inc., Minneapolis, USA) was used. The goal was to 
maximize the percent drug loading and stability while minimizing percent water absorption. 
A 14-run, 5-replicate, D-optimal mixture design was employed to evaluate the effect of PVP 
(X1), Eudragit® RL PO (X2), and α-tocopherol (X3) concentrations on drug loading (Y1), 
water absorption (Y2) and stability (Y3).
Characterization of solid dispersions of DTPA penta-ethyl ester
Evaluation of drug loading—In our previous study,[7] we demonstrated that a single-
dose treatment of 40 mg/kg DTPA penta-ethyl ester improved decorporation of 241Am in 
rats, compared to a no-treatment control group. Thus, we designed a matrix that could 
contain a high weight/weight percentage of prodrug to accommodate large doses. We were 
concerned that loading of the prodrug could be affected by the ratio of PVP to Eudragit® RL 
PO. Thus, the amount of DTPA penta-ethyl ester in various samples was quantified using an 
HPLC system (Shimadzu fitted with a Corona charged aerosol detector (CAD) (Dionex/
ESA, USA). The DTPA penta-ethyl ester matrix was weighed accurately and then dissolved 
in acetonitrile/ethanol (1:1). For each formulation, four matrices were analyzed by the 
HPLC-CAD method, and drug-free excipient mixtures served as controls. The drug loading 
was calculated as follows:
[Eq. 
1]
The column was an Alltima™ C18 (250 mm × 2.1 mm; 5 µm) (Grace Davison Discovery 
Sciences) and maintained at 40 °C. The flow rate was 0.20 mL min−1; the mobile phase was 
water with 0.1% trifluoroacetic acid (A), acetonitrile (B), and isopropanol (C). The mobile 
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phase mixture (A–B–C) followed a linear gradient from 94:4:2 to 10:60:30 over 6.5 min, 
followed by an isocratic phase of 10:60:30 for 4.5 min.[7] The HPLC was validated as 
described previously.[23]
Evaluation of weight variation—Twenty DTPA penta-ethyl ester matrices of each 
formulation were selected randomly and the average weight was determined. Individual 
matrices were then weighed and these were compared to the average weight.
Evaluation of water absorption—Water absorption capacity of the DTPA penta-ethyl 
ester matrix was determined by weighing DTPA penta-ethyl ester matrices before and after 
storage at room temperature and exposure to a relative humidity of approximately 80% (a 
saturated solution of sodium chloride in the glass chamber). After storage and exposure, the 
weight was monitored until no further change was observed. The water absorption capacity 
of the DTPA penta-ethyl ester matrix was calculated using the Equation 2; an average of ten 
readings is reported.
[Eq. 2]
where Wa is weight after storage of DTPA penta-ethyl ester matrix and Wb is weight before 
storage of DTPA penta-ethyl ester matrix.
Fourier transform infrared (FTIR) spectroscopy—FTIR spectra of DTPA penta-
ethyl ester, PVP, α-tocopherol, Eudragit® RL PO and DTPA penta-ethyl ester matrix were 
obtained using a Shimadzu Prestige-21 FTIR spectrometer and IRsolution FTIR control 
software. Thirty two scans were obtained at a resolution of 4 cm−1 from 4,000 to 400 cm−1.
Differential scanning calorimetry (DSC)—The thermal behavior of the DTPA penta-
ethyl ester, PVP, α-tocopherol,Eudragit® RL PO and DTPA penta-ethyl ester matrix was 
determined using DSC (Perkin Elmer DSC 6, USA). Samples of approximately 10 mg were 
placed into a crimped aluminum pan and scanned from 40 to 180°C at a heating rate of 5°C 
min−1. Samples were maintained under a nitrogen atmosphere, which was fed at a flow rate 
of 40 mL min−1.
Dissolution studies—The dissolution profiles of neat DTPA penta-ethyl ester were 
obtained using a USP dissolution Type II apparatus (Hanson Research Elite 8, Chatsworth, 
CA) with a paddle rotation speed of 50 rpm in 900 mL 0.1 N HCl at 37°C for 2 h. An 
HPMC capsule (Size: 0) was filled with 200 mg of DTPA penta-ethyl ester and 
subsequently placed in the dissolution medium. For dissolution studies with the optimized 
formulation of DTPA penta-ethyl ester-matrix, 300 mg of matrices containing 195 mg 
DTPA penta-ethyl ester were placed into 900 mL of 0.1 N HCl (pH 1.2) and incubated at 
37°C for 2 h. The DTPA penta-ethyl ester matrices were then transferred to 900 mL of 
phosphate buffer, pH 6.8, and incubated at 37°C for an additional 2 h. At specific time 
intervals, an aliquot (0.5 mL) was withdrawn and passed through a 0.2 µm PVDF filter. The 
DTPA penta-ethyl ester content was then determined by HPLC-CAD. Dissolution studies 
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were performed in triplicate and calculated mean values of cumulative drug release were 
used for plotting the release curves.
Stability assessment—DTPA penta-ethyl ester matrix samples were stored in closed 
glass screw-cap vials at 40 ± 2 °C and 75 ± 5% relative humidity for one month for the 
accelerated stability tests. Drug remaining in the matrices was analyzed using a previously 
developed HPLC-CAD method.
Statistical analysis—Data are presented as the mean ± SEM. Each experiment was 
repeated at least three times. An unpaired t test was used to establish the significance of 
differences among groups. Differences were considered statistically significant at P < 0.05.
Results and discussion
Solid dispersion of DTPA penta-ethyl ester
The DTPA penta-ethyl ester matrix is shown in Figure 1. Its diameter and height were 5.5 
mm and 5 mm, respectively, and its weight approximately 70 ± 4 mg. There were no 
significant differences in weight among the DTPA penta-ethyl ester matrixes formulated (P 
> 0.05).
Data analysis
Observed responses in D-optimal mixture design for the DTPA penta-ethyl 
ester matrix—The values for percent drug loading, water absorption and stability of the 
prodrug are presented in Table 1. A drug loading of 75% was chosen because the resulting 
weight of DTPA penta-ethyl ester in the matrix would correspond to the dose required in 
vivo, 40 mg kg−1 (75 µmol kg−1), to improve decorporation of 241Am after oral 
administration to rats.[7] For drug loading, there were no significant differences among the 
prepared DTPA penta-ethyl ester matrixes (P > 0.05). Table 2 shows the area of DTPA 
penta-ethyl ester peak decreased while drying at 40°C for 24 h. The result demonstrated that 
approximately 4% of the DTPA penta-ethyl ester underwent degradation after 24 h of 
storage at 40°C. Water absorption and stability were dependent upon the concentration of 
the three excipients, PVP, Eudragit® RL PO and α-tocopherol. The minimum water 
absorption (4.3%) corresponds to the highest Eudragit® RL PO concentration (13.5%) and 
lowest PVP concentration (10%). Increasing the fraction of PVP, a hydrophilic polymer 
which readily absorbs up to 40% of its own weight under 80% relative atmospheric 
humidity,[24] resulted in an increase in the percent water absorbed. There was no phase 
separation observed in any of the formulations, and the stability results showed that the 
percent of intact DTPA penta-ethyl ester in the matrix after one month of storage under 
accelerated storage conditions ranged from 42.2–82.0%. The greatest stability was observed 
when using high concentrations of α-tocopherol (1.5%) and Eudragit® RL PO (13.5%). 
Stability studies with neat DTPA penta-ethyl ester showed that only 34% of the drug 
remained after storage at 40 ± 2°C (75 ± 5% relative humidity) for 1 month (data not 
shown), which is lower than that in all matrixes. Thus, it appears that the stability of DTPA 
penta-ethyl ester can be increased after formulating it in a solid dispersion. Due to the 
presence of five esters in its structure, the prodrug is unstable in high-temperature, high-
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humidity environments, as ester prodrugs are susceptible to degradation by hydrolytic 
cleavage.[25] Our pre-formulation studies showed that hydrolysis is the major mechanism by 
which the prodrug degrades. An examination of the HPLC chromatograms (Figure 2) of 
degraded samples revealed the presence of DTPA tetra-ethyl ester, DTPA tri-ethyl ester, and 
DTPA di-ethyl ester.
Data fitting—Models for fitting the data were considered significant when the p value was 
<0.05.[26] From the p values presented in Table 3, it can be concluded that the best model 
for Y1, Y2 and Y3 is linear. R2 values for Y1, Y2 and Y3 were 0.791, 0.935 and 0.885, 
respectively, indicating good correlation between dependent and independent variables. 
Furthermore, the three linear models had large adjusted and predicted R2 values as well as 
small standard deviations (SD). These predicted residual sum of squares (PRESS), shown in 
Table 3, further exemplifying their suitability to fit the data. The following equations show 






A positive value indicates a synergistic effect and a negative value represents an antagonistic 
effect. The coefficients of X1 for Y2 responses show that a synergistic effect was observed 
for water absorption. Thus, as expected, an increase in PVP resulted in an increase in water 
absorption; therefore, a lower ratio of PVP is preferred here. The coefficients of the X3 for 
Y3 responses demonstrate that α-tocopherol is the most important component for stability of 
the prodrug in the matrix.
Contour plot analysis—Two dimensional contour plots are presented in Figure 3 and 
show the effects of three components (PVP, Eudragit® RL PO and α-tocopherol) on 
dependent variables. The contour plot shows that drug loading is not significantly affected 
by the ratio of formulation ingredients (Figure 3A). The water absorption of the 
formulations was dependent on the concentration of PVP and Eudragit® RL PO (Figure 3B). 
Increasing the fraction of Eudragit® RL PO decreased water absorption as expected due to 
its hydrophobic properties. Contour plots for stability showed that increasing concentrations 
of α-tocopherol and Eudragit® RL in the formulation resulted in an increase in the stability 
of DTPA penta-ethyl ester in the matrix (Figure 3C).
Optimization of the DTPA penta-ethyl ester-matrix formulation—The optimum 
formulation of DTPA penta-ethyl ester-matrix (batch 4) was selected based on maximum 
percent drug loading, stability and minimum water absorption. The optimized formulation 
was achieved with 10% PVP, 13.5% Eudragit® RL PO and 1.5% α-tocopherol; it had drug 
loading of 64.7% with water absorption and stability of 4.3% and 82.0%, respectively.
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Interactions between drug and carrier can lead to identifiable changes in the FTIR spectrum 
of a solid dispersion. Thus, FTIR spectra of DTPA penta-ethyl ester, PVP, Eudragit® RL 
PO, α-tocopherol and the DTPA penta-ethyl ester matrix were obtained (Figure 4). The 
spectra of DTPA penta-ethyl ester and Eudragit® RL PO have absorptions at 2983, 1732, 
1190 and 1029 cm−1, which correspond to sp3 CH2 and CH3, C=O, C-O and C-N stretching 
vibrations, respectively. In the PVP spectrum, the absorption at 1654 cm−1 corresponds to 
the stretching vibration of the C=O on the pyrrolyl ring.[13, 27] The α-tocopherol spectrum 
has absorptions at 3450 cm−1 (O-H stretching), 2927 and 2868 cm−1 (asymmetric and 
symmetric sp3 CH2 and CH3 stretching), 1,262 cm−1 (CH2 bending), 1,086 cm−1 (CH in-
plane bending on the phenyl ring) and 919 cm−1 (-CH=CH-(trans) stretching).[28] In the 
FTIR spectrum of the DTPA penta-ethyl ester matrix, absorptions associated with DTPA 
penta-ethyl ester and excipients are observed that do not differ significantly in position from 
their individual spectra. These results suggest that the DTPA penta-ethyl ester and excipients 
do not exhibit solid-solid interactions with each other during formulation of the solid 
dispersion.
Thermal analysis
DSC curves obtained for neat DTPA penta-ethyl ester, PVP, α-tocopherol, Eudragit® RL 
PO and the DTPA penta-ethyl ester matrix (batch 4) are shown in Figure 5. No thermal 
phase transitions were observed for neat DTPA penta-ethyl ester or α-tocopherol, when the 
temperature was raised from 40 to 180°C. Eudragit® RL PO had a glass transition 
temperature at 57°C, and during the scanning of PVP, a broad endothermic peak ranging 
from 60 to 120°C was observed, probably due to the presence of water. As expected, no 
peaks were present in the thermogram of the solid dispersion of the optimized formulation 
indicating that the matrix had an amorphous structure.
Dissolution
The dissolution profiles of neat DTPA penta-ethyl ester in 0.1 N HCl (pH 1.2) and the 
optimized DTPA penta-ethyl ester matrix formulation (batch 4) in 0.1 N HCl and phosphate 
buffer(pH 6.8) are shown in Figure 6. The dissolution rate of DTPA penta-ethyl ester was 
faster than that of the DTPA penta-ethyl ester matrix in pH 1.2 medium in the first two 
hours. Approximately 96% of the drug was released after 45 min when using neat DTPA 
penta-ethyl ester. In contrast, a slower release of drug was observed when using the 
optimized formulation; approximately 85% of drug was released in the acidic dissolution 
medium after two hours, and 100% two hours after the medium was changed to a pH 6.8 
solution. The solid dispersion polymer of DTPA penta-ethyl ester in the matrices strongly 
affected drug dissolution rate, and thehe slower release of DTPA penta-ethyl ester from the 
matrix was likely due to the addition of Eudragit® RL PO polymer in the formulation. 
Eudragit RL is a water-insoluble polymer, and it shows the pH-independent sustained drug 
release attributed to the quaternary ammonium groups.[17, 18] The optimized solid dispersion 
appears to allow for sustained delivery of DTPA penta-ethyl ester to the intestines. This is 
advantageous for radionuclide decorporation therapy where sustained blood levels of 
chelating agents are desirable for removing circulating radionuclides from the bloodstream.
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DTPA penta-ethyl ester was successfully incorporated into a solid matrix with high drug 
loading and improved stability compared to neat prodrug. The results of the D-optimal 
mixture design indicated that having a high concentration of both Eudragit® RL PO and α-
tocopherol favored low water absorption and enhanced stability of DTPA penta-ethyl ester 
in the matrix; no significant differences between formulations in percent loading of the 
prodrug were ever observed, however. DSC studies indicated that the matrix has an 
amorphous structure, and FTIR spectrometry showed that there are no interactions between 
drug molecule and excipients in the solid dispersion. Future efforts are being devoted to 
preparing a polymer-coated solid dispersion to further protect the active ingredient from 
hydrolytic and oxidative degradation.
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Appearance of the DTPA penta-ethyl ester matrix.
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Chromatograms of freshly prepared DTPA penta-ethyl ester that was stored at 40°C for 24 
h.
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Contour plots showing the effect of PVP, Eudragit® RL PO and α-tocopherol on drug 
loading (A), water absorption (B) and 1 month stability of DTPA penta-ethyl ester at 
40°C/80% relative humidity (C).
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FTIR spectra of the optimized DTPA penta-ethyl ester matrix, neat DTPA penta-ethyl ester, 
PVP, Eudragit® RL PO and α-tocopherol.
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DSC traces of neat DTPA penta-ethyl ester, PVP, α-tocopherol, EudragitRL PO and DTPA 
penta-ethyl ester matrix at a scanning rate of 5°C min-1.
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Amount released of the neat DTPA penta-ethyl ester in 0.1 M HCl (2 h) (A) and from matrix 
in 0.1 M HCl (2 h) and then PBS, pH 6.8 (2 h) (B).
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Table 2
The area of DTPA penta-ethyl ester with freshly prepared and storage for 24 h at 40°C
Retention time (min) Area
Freshly prepared 11.547 1428280
24 hr (40°C) 11.553 1372973
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